Breaking the log-jam in treatment development for cognition in schizophrenia: NIMH perspective

Psychopharmacology

Volumn 169, Issue 3-4, 2003, Pages 365-366

  Fenton, Wayne S ^a   Stover, Ellen L ^b   Insel, Thomas R ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR BLOCKING AGENT;

COGNITION; COGNITIVE DEFECT; DRUG EFFICACY; EDITORIAL; GOVERNMENT; HUMAN; INDUSTRY; MEDICAL ASSESSMENT; NEUROBIOLOGY; NEUROPHARMACOLOGY; PRIORITY JOURNAL; SCHIZOPHRENIA;

ANIMALS; COGNITION DISORDERS; HUMANS; NATIONAL INSTITUTE OF MENTAL HEALTH (U.S.); PSYCHOPHARMACOLOGY; SCHIZOPHRENIA; UNITED STATES;

EID: 0141889787     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-003-1564-1     Document Type: Editorial

References (5)

1. Buchanan RW, Carpenter WT Jr (1997) The neuroanatomies of schizophrenia. Schizophr Bull 23:367-372
2. Carpenter WT, Gold JM (2002) Another view of therapy for cognition in schizophrenia. Biol Psychiatry 51:972-978
3. Fujii DE, Wylie AM (2003) Neurocognition and community outcome in schizophrenia: long-term predictive validity. Schizophr Res 59:219-223
4. Hyman SE, Fenton WS (2003) What are the right targets for psychopharmacology? Science 299:350-351
5. Sharma T, Antonova L (2003) Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. Psychiatr Clin N Am 26:25-40